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Abstract
Objective: Investigation of the interplay between the CCR5 D32/wt genotype and demographic, epidemiological, clinical
and immunological factors associated with mortality in the cART era.
Design: Longitudinal data from 507 HIV-infected patients following the D32 allele detection were analyzed.
Methods: Cumulative 15 years mortality was calculated using Kaplan-Meyer methodology. Hazard ratios were estimated
using univariate Cox models. Basing on Akakie information criteria and statistical significance multivariate Cox model was
constructed and effect plots presenting adjusted hazard ratio time-dependency were drawn. Analysis of the association of
all-cause mortality and CCR5 D32/wt genotype prior to the antiretroviral treatment (cART) initiation (n=507) and on the
therapy (n=422) was also performed.
Results: A mortality rate of 2.66 (CI 2.57–3.19) per 100 person-years was observed. Univariate analysis factors modifying the
risk of death included the CCR5 genotype, gender, history of cART, AIDS diagnosis and also CD4 lymphocyte nadir, zenith,
the latest CD4 count and stable levels .500 cells/ml. For multivariate analysis the following predictors were selected: CCR5
genotype (HR for wt/wt 2.53, CI 1.16–5.53, p=0.02), gender (HR for males 1.91, 95%CI 1.1–3.36, p=0.023), introduction of
combined antiretroviral treatment (HR 4.85, CI 3.0–7.89, if untreated or treated ,1 month, p,0.0001) CD4 count of 500
cells/ml for six months or more (HR 4.16, CI 1.95–8.88 if not achieved, p=0.028), the latest CD4 count (HR 5.44, CI 3.39–8.74
for ,100 cells/ml, p,0.0001) and history of AIDS (HR 1.69, CI 1.03–2.79, p=0.039). Among untreated individuals the D32/wt
genotype was associated with notably better survival (p=0.026), while among cART treated individuals the D32 mutation
did not correlate significantly with higher survival rates (p=0.23).
Conclusions: The D32 CCR5 allele is associated with a reduction of the risk of all-cause mortality in HIV (+) patients alongside
clinical and immunologic predictors such as AIDS, history of cART, lymphocyte CD4 cell count and gender.
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Introduction
Infection with the human immunodeficiency virus type 1 (HIV-
1) requires attachment to one of the principal chemokine
coreceptors, namely CCR5 and CXCR4 for effective entry into
CD4+ T-cells [1]. Use of CCR5 is frequently associated with the
early stages of infection while progression of human immunode-
ficiency virus infection to AIDS and death is related to a viral
tropism switch to CXCR4 [2]. Genetic variants of the chemokine
receptors and their ligands modify susceptibility to HIV infection
and the course of the disease, with a 32 base pair deletion (D32)i n
the reading frame of the CCR5 gene associated with reduced
susceptibility to infection and delayed disease progression [3,4].
D32/D32 homozygotes remain resistant to infection with CCR5
tropic variants of HIV, while among heterozygous D32/wild-type
(wt) subjects beneficial, AIDS protective effects, have been noted in
the early years of infection [5,6]. Studies of the long-term non-
progression among HIV-infected patients have indicated higher
frequency of this protective allele among individuals spontaneously
controlling the infection [7]. This variant has also been associated
with better virologic response to combined antiretroviral therapy
(cART) as well as less frequent virologic failure, decreased risk of
early death among perinatally infected children and protection
from AIDS among antiretroviral-treated patients [8–11].
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expected long term survival an array of interplaying factors
influence mortality among people living with HIV. Lymphocyte
CD4 metrics, early introduction of antiretroviral treatment and
preservation of immunological function are the key contributors to
the risk of mortality in this group [12,13]. As the interaction
between clinical, immunological, virologic factors and genetic
variants influencing survival have not been studied so far in detail
this study aimed to evaluate the impact of CCR5 D32 mutation on
the long-term mortality of patients living with HIV. Character-
istically in Europe, as well as in Poland, most HIV cases are
diagnosed late necessitating immediate initiation of combined
antiretroviral treatment [14,15]. Therefore the rationale for this
analysis was that beneficial effects of the mutation are likely to be
disproportionately seen in this population due to a protective effect
prior to diagnosis, enhanced by a favorable effect following
initiation of the antiretroviral treatment.
Materials and Methods
Study population
For the study longitudinal data of 507 patients followed-up from
January 1996 to June 2010 at the Department of Infectious
Diseases and Hepatology, Pomeranian Medical University,
Szczecin, Poland and Out Patients’ Clinic for Acquired Immuno-
deficiency, Regional Hospital, Szczecin, Poland were analyzed.
The study protocol was approved by the bioethical committee of
Pomeranian Medical University, Szczecin, Poland (approval
number BN-001/34/04). Written informed consent was obtained
from all subjects participating in the study. Time zero was defined
as a date of positive screening HIV test if later confirmed by
Western-blot, immunoblotting or positive serum HIV-RNA or a
confirmation test itself. The following data were collected: age,
gender, date of HIV diagnosis, route of transmission, hepatitis C
co-infection, clinical category at diagnosis according to CDC case
definition [16], date and diagnosis of AIDS events, date and
reason of death, baseline HIV viral load, history of cART as well
as baseline, nadir, zenith and the latest CD4 counts, duration of
CD4 count .500 cells/ml. Baseline CD4 counts are defined as the
first documented result after diagnosis of HIV. Data on nadir and
zenith (the lowest and the highest lymphocyte CD4 count
throughout the period of observation) lymphocyte CD4 counts
were collected as well. The latest lymphocyte CD4 count was
taken as the last recorded value prior to the end of observation or
death. CDC category at diagnosis was assumed based on the
review of the clinical record of the patient, in cases of late care
entry with documented prior HIV test category A (asymptomatic)
was assumed if no apparent immunodeficiency was reported or
available from medical records. Data on chronic hepatitis B were
not included into the analysis due to small number of confirmed
HIV/HBV co-infection cases while the parameter of the latest
HIV-RNA levels was removed as it was performed only in 60% of
patients, often being collected up to one year from the date of final
observation, which was related to the poor availability of the assay.
Study endpoint
Study endpoint was defined as all-cause mortality excluding
cases with documented accidental death. Determination of the
reason of death was based on the following data: autopsy report
(42 cases), medical record of in-hospital treatment with cause of
death defined by the treating physician (32 cases), other medical
report or letter (19 cases); in four cases the cause of death remained
undetermined. Validation of the underlying cause of death was
performed by an independent clinician not involved in the patient
care with discrepancies in the data thoroughly discussed. AIDS
related death was assumed if the criteria (either presumptive or
definitive) outlined by the CDC case definition were met with at
least one AIDS defining condition observed at the time of death.
End of observation date was defined as either death date, last
recorded date of visit (cases lost to follow-up) or 1
st of June 2010
for the patients remaining under care (termination of data
collection). When it was impossible to determine the exact date
of death (6 cases) the median date between the last recorded visit
and information on death was assumed as the death date.
DNA extraction and CCR5 genotyping
For genomic DNA extraction from whole blood samples
QIAamp DNA Blood Mini Kit (QIAgen, Hilden, Germany) was
used with re-suspended DNA stored at 4uC for further analyses. If
whole blood samples were unavailable frozen serum samples were
used with extraction performed using Sherlock AX kits (A&A
Biotechnology, Gdynia, Poland). For the CCR5 D32/wt genotyp-
ing a previously described methodology was used [17] with
reaction products electrophoresed on a 3% agarose gel (SIGMA,
Saint Louis, USA) stained with DNA-star dye (Lonza Inc,
Rockland, USA) and visualized under UV light.
Statistics
Statistical analyses for nominal variables were performed with
chi-square test using EPI6 Statcalc software (Department of
Mathematics, University of Louisiana-Lafayette, Lafayette, LA,
USA), for continuous variables, the Mann–Whitney U-test was
used (Statistica software, Statsoft, Tulsa, OK, USA). Cox models
for survival were used to assess the effect of analyzed parameter on
the risk of death. For all analyzed parameters unadjusted
(univariate) Cox models were used to calculate the hazard ratio
(HR) and included CCR5 genotype, transmission route, hepatitis C
co-infection, HIV infection stage at diagnosis, history of
antiretroviral treatment, baseline viral load (log HIV-RNA
copies/ml), baseline CD4 count (cells/ml), nadir CD4 count
(cells/ml), zenith CD4 count (cells/ml), time with CD4 count .500
cells/ml, the most recent CD4 count (cells/ml) and history of AIDS.
Moreover, for every parameter Kaplan-Meyer cumulative mor-
tality was calculated and plotted with statistical significance testing
using log-rank test. To select the most informative parameters for
the multivariate model Akaike information criteria (AIC) were
used to assess the fit of the each model (lower AIC indicates better
fit) [18]. A final multivariate model was calculated by Cox
regression for the 15-year observation and effect plots presenting
adjusted hazard ratio changes over time were drawn for this
model. To test the proportional hazards assumption for the
multivariate Cox regression model coxph function of the R
package was used. P-values of ,0.05 were considered significant
with values in the range of 0.1–0.05 regarded as borderline
statistically significant.
Results
Patient characteristics
In the analyzed group of 507 HIV (+) patients the CCR5 D32
genotype frequency was 14.0% with D32 allele frequency of 7.0%.
No D32/D32 homozygotes were observed in the group. All
patients were of Caucasian ethnicity with predominance of men
(n=363, 79.5%), median baseline age of 30 years, 50.0% infected
by injection drug use, median (inter quartile range - IQR) baseline
CD4 count of 229 (634-518) cells/ml and median (IQR) viral load
of 74000 (14222–315000) HIV-RNA copies/ml (table 1). Mean
(IQR) time of observation in the group was 83 (33-129) months.
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AIDS-free time was 52 (11-115) months; antiretroviral treatment
was initiated in 84.5% of patients.
Notable differences in the frequency of the CCR5 D32 genotype
were observed for baseline CDC category (CCR5 D32/wt genotype
frequency among individuals diagnosed at asymptomatic stage of
infection was 22.0% compared to 10.2% among symptomatic and
AIDS patients, p,0.003) and overall number of deaths (the CCR5
D32/wt genotype was observed in 7.5% cases compared to 15.6%
of patients surviving throughout the period of observation,
p=0.046). Similar CCR5 D32/wt genotype frequency was
observed among patients with AIDS related deaths (7.6%) while
in the group with non-AIDS related death the frequency of the
CCR5 D32/wt genotype was lower (5.0%, p=0.073 if compared to
the entire surviving group). Other differences with borderline
significance in the CCR5 D32/wt genotype distribution included
transmission route (16.1%, 11.8%, and 14.2% for homosexual,
heterosexual and injection drug use (IDU) related transmissions,
respectively, p=0.07), female vs. male gender (9.7% and 15.7%,
respectively, p=0.08) and initiation of antiretroviral treatment
(20.0% among treatment naive individuals vs. 13.0% among
cART treated patients, p=0.09). Majority of women with the D32
allele were infected sexually (n=9, 64.2%), while among men
predominated IDU (n=32, 56.1%) over sexual transmissions
(homosexual route was observed in 18 (31.6%) while heterosexual
in 7 cases (12.3%) (p=0.17). No significant difference between the
groups with and without the D32 allele in the overall number of
AIDS diagnoses was observed (the CCR5 D32/wt genotype noted in
Table 1. Group characteristics by the CCR5 genotype.
CCR5 D32/wt
genotype
CCR5 wt/wt
genotype total
CCR5 D32/wt genotype
frequency (%) p value
No. of patients* (%) 71 (14.0) 436 (86.0) 507 (100) 14.0 n/a
Gender
female (% of total) 14 (2.76) 130 (25.64) 144 (28.4) 9.72 0.08
male (% of total) 57 (11.24) 306 (60.36) 362 (71.6) 15.7
Clinical category at diagnosis
A (% of total) 44 (8.92) 156 (31.64) 200 (40.57) 22.0 0.003
B (% of total) 14 (2.84) 164 (33.27) 178 (36.11) 7.87
C (% of total) 13 (2.64) 102 (20.69) 115 (23.33) 11.3
Likely infection mode
MSM (% of total) 18 (3.58) 94 (18.6) 112 (22.27) 16.07 0.07
Heterosexual (% of total) 16 (3.18) 120 (23.86) 136 (27.04) 11.76
Injection Drug Use (% of total) 36 (7.16) 218 (43.34) 254 (50.50) 14.17
History of cART during follow-up
cART .1 month (% of total) 55 (10.93) 368 (73.16) 423 (84.1) 13.0 0.1
Never on cART or ,1 month (% of total) 16 (3.18) 64 (12.72) 80 (15.9) 20.0
History of Hepatitis C
HIV/HCV coinfected (% of total) 40 (8.62) 224 (48.28) 264 (56.9) 12.0 0.32
HIV monoinfection (% of total) 24 (5.17) 176 (38.93) 200 (43.1) 15.5
Diagnosis of AIDS during follow-up
AIDS diagnosed (% of total) 24 (4.73) 169 (33.33%) 193 (38.07) 12.44 0.42
AIDS-free (% of total) 47 (9.27) 267 (52.66) 314 (61.93) 14.97
Mortality
All-cause death (% of total) 7 (1.38) 86 (16.96) 93 (19.13) 7.53 0.05
Aids related death (% of total) 5 (0.98) 48 (9.46) 53 (10.45) 7.58 0.31
Non-AIDS related death (% of total) 2 (0.03) 38 (7.45) 40 (7.89) 5.0 0.07
Immunologic and virologic characteristics
Median baseline lymphocyte CD4
count (IQR) (cells/ml)
280 (44–539) 209 (64–417) 229 (63.5–417.5) n/a 0.2
Median nadir lymphocyte CD4
count (IQR) (cells/ml)
171 (41–332) 138 (47–300) 147 (46–303) n/a 0.33
Median zenith lymphocyte CD4
count (IQR) (cells/ml)
539 (380–810) 520 (316–780) 522 (322–780) n/a 0.42
Median baseline viral load (IQR) (copies/ml) 85200 (21600–310000) 70500 (14000–320000) 74000 (14222–315000) n/a 0.94
n/a – non-applicable. Sample sizes vary due to data availability: CCR5 genotype, gender, AIDS diagnosis – 507 persons, HCV co-infection status - 464 persons,
transmission route and history of antiretroviral treatment – 503 persons, HIV infection stage at diagnosis – 489 persons, baseline viral load (log copies/ml) – 288 persons,
baseline lymphocyte CD4 count (cells/ml) – 488 persons, nadir lymphocyte CD4 count (cells/ml) – 494 persons, zenith lymphocyte CD4 count (cells/ml) – 499 persons, time
with lymphocyte CD4 count .500 cells/ml – 500 persons, latest lymphocyte CD4 count – 504 persons.
doi:10.1371/journal.pone.0022215.t001
All-Cause Mortality and the CCR5 D32 Deletion
PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e2221515.0% of AIDS free cases vs. 12.4% of patients with the syndrome,
p=0.42) but the AIDS-free time was slightly longer among HIV
positive patients with the CCR5 D32/wt genotype (median (IQR)
of 75(19-134) vs. 48 (10-109) months, p=0.14), despite similar age
at diagnosis (median (IQR) for the CCR5 D32/wt of 29 (25-35) vs.
30 (25-38) years of age for CCR5 wt/wt, p=0.62) and observation
time (85 (41-148) for the CCR5 D32/wt vs. 82 (33-19) months for
CCR5 wt/wt, p=0.23).
Figure 1. Causes of AIDS-related deaths and CCR5 wt/wt vs. CCR5 D32/wt genotype.
1 AIDS-related malignancy: B-cell lymphoma (n=4),
Burkitt lymphoma (n=1), immunoblastic lymphoma (n=1), primary CNS lymphoma (n=4), non-Hodgkin lymphoma - unspecified location (n=2);
2 Fungal infection: pulmonary candidosis (n=2), generalised cryptococcosis (n=1);
3 Tuberculosis: pulmonary (n=4), tuberculotic sepsis (n=3).
doi:10.1371/journal.pone.0022215.g001
Figure 2. Causes of non AIDS-related deaths and CCR5 wt/wt vs. CCR5 D32/wt genotype.
1 Hepatic: liver cirrhosis (n=5), liver insufficiency
(n=3);
2 CVD: stroke (n=1), coronary artery disease (n=2), pulmonary embolism (n=1);
3 Non AIDS-related malignancy: Hodgkin lymphoma (n=1),
gastric cancer (n=1), leukemia (n=1), testicular cancer (n=1). Gestosis: death related to pre-eclampsia or eclampsia during pregnancy.
doi:10.1371/journal.pone.0022215.g002
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Predictor HR
1
p (Cox
regression)
Lower
95%CI
Upper
95%CI
5-years
KM death
estimate
(%)
10-years
KM death
estimate
(%)
15-years
KM death
estimate
(%)
p value for
15 year KM
estimate
(log-rank test) AIC*
CCR5 genotype
Wt/D32 reference 3.23 14.45 20.56 0.026 1090.89
Wt/wt 2.28 0.039 1.06 4.92 12.74 25.85 33.57
Transmission route
IDU reference 10.03 25.76 33.02 0.939 1096.48
SEX 0.98 0.939 0.65 1.48 12.35 20.91 28.98
Hepatitis C co-infection status
HCV (2) reference 8.28 18.05 28.22 0.566 1096.27
HCV (+) 1.15 0.556 0.72 1.86 9.43 21.65 28.73
Gender
Female reference 8.60 13.49 19.33 0.017 1090.17
Male 1.90 0.019 1.11 3.25 12.49 28.09 36.12
HIV infection stage at diagnosis
Asymptomatic reference 4.91 22.94 29.10 0.09 1093.66
Symptomatic 1.43 0.096 0.94 2.18 15.15 24.24 33.55
History of antiretroviral treatment
cART .1 month reference 8.91 18.47 27.13 ,0.0001 1068.35
Never on cART
or ,1 month
3.83 ,0.0001 2.46 5.98 26.11 62.84 62.84
Baseline viral load (log copies/ml)
VL baseline* .5l o g reference 6.49 12.77 18.21 0.526 n/a*
VL baseline ,5 log 1.25 0.523 0.63 2.45 10.11 16.55 22.97
Baseline lymphocyte CD4 count (cells/ml)
CD4 baseline .100 reference 7.73 18.91 27.34 0.0002 1082.41
CD4 baseline ,100 2.26 0.0001 1.49 3.41 19.07 33.49 41.10
CD4 baseline .50 reference 8.53 19.38 27.67 ,0.0001 1081.24
CD4 baseline ,50 2.46 ,0.0001 1.61 3.77 21.09 38.87 45.79
CD4 baseline .25 reference 9.56 22.68 30.27 0.022 1092.29
CD4 baseline ,25 1.76 0.028 1.060 2.920 21.46 29.02 40.21
Nadir lymphocyte CD4 count (cells/ml)
CD4 nadir .100 reference 6.34 17.66 20.87 0.0003 1084.79
CD4 nadir ,100 2.17 0.0004 1.42 3.34 16.54 28.06 40.88
CD4 nadir .50 reference 7.51 17.13 22.17 ,0.0001 1080.51
CD4 nadir ,50 2.50 ,0.0001 1.64 3.8 18.33 33.81 46.66
CD4 nadir .25 reference 8.97 20.27 26.81 0.014 1091.46
CD4 nadir ,25 1.80 0.014 1.13 2.88 17.55 29.48 42.41
Zenith lymphocyte CD4 count (cells/ml)
CD4 zenith .500 reference 2.60 8.34 10.79 ,0.0001 1046.57
CD4 zenith ,500 5.51 ,0.0001 3.25 9.34 20.79 38.80 48.77
Time with lymphocyte CD4 count .500 cells/ml
At least 180 days reference 1.15 5.43 7.06 ,0.0001 1047.98
Less than 180 days 7.73 ,0.0001 3.741 16.00 17.50 34.17 43.80
At least one year reference 0.71 4.74 6.71 ,0.0001 1057.46
Less than one year 7.95 ,0.0001 3.47 18.20 15.54 31.32 40.39
Most recent lymphocyte CD4 count (cells/ml)
Last CD4 .500 reference 2.42 7.74 11.26 ,0.0001 1062.36
Last CD4 ,500 4.84 ,0.0001 2.582 9.085 16.33 32.33 41.57
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In the group there were 97 deaths observed, 55 (56.7%) being
AIDS-related and 42 (43.3%) non-AIDS related. All-cause
mortality of 2.66 (95%CI 2.57–3.19) per 100 person-years with
AIDS-related mortality of 1.51 (95% CI 1.44–1.90) and non-
AIDS related of 1.15 (95% CI 1.09–1.50) per 100 person-years
was noted. The most common causes of AIDS related deaths
were pneumonia, malignancy and tuberculosis while drug
overdose, endocarditis and hepatic events were leading causes
of non-AIDS related deaths (figure 1 and 2). In seven patients
who died (7.5%) the CCR5 wt/D32 genotype was noted, in
majority of these patients (n=5) AIDS-defining conditions were
observed at the time of death while two deaths were non-AIDS
related. There were no significant differences for the reasons of
death between the groups with and without the CCR5 D32
allele.
Association between mortality and selected factors
Table 2 shows univariate hazard ratios calculated with Cox
regression and Kaplan-Meyer cumulative mortality for all
parameters investigated in the study. Additionally, for every
parameter included, Akaike information criterion (AIC) is
presented to indicate the fitness of association with mortality.
Identified predictors associated with a significantly greater
mortality included the CCR5 genotype, male gender, symptom-
atic HIV infection at diagnosis, antiretroviral treatment history
and AIDS diagnosis (figure 3a–e). The analysis also included a
range of lymphocyte CD4 metrics, namely baseline, nadir,
zenith and the most recent CD4 count and time of observation
with CD4 above 500 cells/ml. Baseline, nadir and the most
recent CD4 counts were further categorized using 100, 50 and
25 cells/ml thresholds; for zenith and time of observation the
500 cells/ml threshold was used. This category was also added in
the calculations for the latest CD4 count. The strongest
association between the baseline and nadir CD4 counts and
mortality was noted for the 50 cells/ml category for baseline and
nadir CD4 count (figure 3f–g) as well as CD4 zenith ,500 cells/
ml (figure 3h) and for patients with the most recent CD4 counts
.500 cells/ml (figure 3i). It must be noted that Akaike
information criterion for the most recent CD4 was the lowest
for 100 cells/ml threshold therefore this value was selected for
the multivariate analysis. Two categories were analyzed for time
with CD4 count .500 cells/ml vs. patients who have never
maintained stably high CD4 counts, namely six and twelve
months, respectively (figures 3k,3l). No statistically significant
differences were obtained for AIDS and non-AIDS related
deaths analyzed separately.
Multivariate survival model with selected parameters
Basing on the AIC and statistical significance for each
parameter a multivariate Cox model was constructed. In the
initial model all parameters presented in table 2 with p#0.1
for univariate HR were included, for parameters with mul-
tiple categories (CD4 metrics) the ones with the lowest AIC
were used. Parameters with p,0.1 were removed during
analysis prior to construction of the final multivariate model.
In the test for the fit of the Cox regression model proportiona-
lity was not violated (p values for all selected variables .0.05,
with global value of 0.367). In multivariate analysis factors
associated with a higher adjusted HR were the CCR5 genotype
(HR for wt/wt homozygotes 2.53 (95%CI 1.16–5.53), p=0.02),
gender (HR for males 1.91 (95%CI 1.1–3.36), p=0.023),
introduction of antiretroviral treatment (HR 4.85 (95%CI 3.0–
7.89) if untreated or treated for less than one month, p,0.0001,
CD4 count of 500 cells/ml for six months (HR 4.16 (95%CI
1.95–8.88) if the parameter was not achieved, p=0.028),
the latest CD4 count (HR 5.44 (95%CI 3.39–8.74) for ,100
cells/ml, p,0.0001) and the history of AIDS (HR 1.69 (95%
CI 1.03–2.79) for patients with this diagnosis), p=0.039 (table 3,
figure 4). Time-dependent HR plots adjusted for each of the
six parameters were drawn to show the effect on survival
(figure 5a–f).
Association between CCR5 D32 genotype and survival in
treated and untreated individuals
To assess the influence of the CCR5 D32 genotype prior to the
cART introduction two additional analyses were performed. The
first one for the untreated individuals (n=507 including 71
individuals with the CCR5 D32/wt genotype), starting from the
HIV diagnosis and censored at the time of the cART initiation,
loss to follow-up or death (figure 6a). The second one was based on
cART treated individuals (n=422, 55 individuals with the CCR5
Predictor HR
1
p (Cox
regression)
Lower
95%CI
Upper
95%CI
5-years
KM death
estimate
(%)
10-years
KM death
estimate
(%)
15-years
KM death
estimate
(%)
p value for
15 year KM
estimate
(log-rank test) AIC*
Last CD4 .100 reference 5.73 13.70 19.98 ,0.0001 1001.18
Last CD4 ,100 9.23 ,0.0001 6.128 13.92 43.52 73.93 87.64
Last CD4 .50 reference 7.18 15.61 23.35 ,0.0001 1011.89
Last CD4 ,50 10.13 ,0.0001 6.619 15.51 47.42 84.76 92.38
Last CD4 .25 reference 8.92 19.76 27.03 ,0.0001 1051.07
Last CD4 ,25 8.48 ,0.0001 5.124 14.07 49.46 79.32 100.0
History of AIDS
AIDS-free reference 6.29 14.66 17.75 ,0.0001 1063.16
AIDS-diagnosed 3.30 ,0.0001 2.582 9.085 19.45 38.48 50.40
*For AIC calculations equal group size was used, baseline viral load was excluded from this calculation due to poor availability (288 individuals only).
1Univariate HR (Hazard Ratio) calculated by unadjusted Cox regression for the same sample sizes as described in the table 1.
doi:10.1371/journal.pone.0022215.t002
Table 2. Cont.
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censoring at the time of termination of data collection, loss to
follow-up or death (figure 6b). Among untreated individuals the
CCR5 D32/wt genotype was associated with better survival
(p=0.026), however among cART treated individuals the D32
mutation did not correlate significantly with higher survival rates
(p=0.23).
Discussion
This study investigates the combined effect of selected
parameters and the CCR5 D32 allele on long term survival
among HIV-1 infected patients in the era of cART. An array
of factors influencing survival were analyzed in this study
including demographics as well as clinical and immunological
Figure 3. Kaplan-Meyer plots for the most significant parameters. a–CCR5 genotype, b- gender, c- HIV infection stage at diagnosis, d –
antiretroviral treatment history, e- AIDS diagnosis, f – baseline CD4 count of .50 cells/ml, g – nadir CD4 cells .50 cells/ml, h – zenith CD4 .500 cells/
ml, i – the most recent CD4 count .500 cells/ml, j- the most recent CD4 count .500 cells/ml, k- CD4 count .500 cells/ml maintained for at least half a
year, l - CD4 count .500 cells/ml maintained for at least one year.
doi:10.1371/journal.pone.0022215.g003
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in this study was 14.0% and is consistent to the previous reports
for Caucasian populations, while use of archived samples
allowed to avoid the bias related to the survival benefit of
the mutation in HIV infected patients who may have died
[8,19,20]. The near-significant difference between the male and
female gender frequency might be related to the transmission
route – higher number of women was infected sexually. It is
possible that the risk of HIV transmission is differently modified
by the D32 allele for every gender, depending on the type of
exposure.
An association between the D32 allele and delayed progression
to AIDS has previously been reported including a suggestion that
this deletion is the strongest protective factor for both viral and
immununologic control of the HIV-associated disease and
improved survival outside the HLA system [10,21]. In the study
by Hendrickson et al. [11], both time to viral suppression and
AIDS free survival following cART initiation was significantly
longer in the group with the D32 allele. In the meta-analysis by
Ioannidis et al., the relative hazard for both AIDS and death was
notably lower among the CCR5 D32/wt heterozygotes if compared
to the individuals homozygous for the wild-type variant [22]. The
Figure 4. Multivariate Cox regression model of factors modifying 15 year mortality among HIV infected patients (favorable versus
unfavorable parameter). Dots represent adjusted hazard ratio (HR) for the unfavorable parameters, lines represent confidence intervals for the HR.
doi:10.1371/journal.pone.0022215.g004
Table 3. Multivariate model of factors associated with probability of survival in the cohort.
Parameter (favorable
vs. unfavorable)
No. (%) of deaths
in the group with
favorable
parameter
No. (%) of deaths
in the group with
unfavorable
parameter
Adjusted
HR
Lower
95% CI
Upper
95% CI
Percentage of the
risk increase for
unfavorable
parameter p value
CCR5 genotype
Wt/D32 vs. wt/wt 7 (9.8) 86 (19.7) 2.53 1.16 5.53 153% 0.02
Gender
Female vs. male 16 (11.1) 81 (22.4) 1.91 1.10 3.36 91% 0.023
cART .30 days
Yes vs. no 68 (16.1) 28 (35.0) 4.85 3.0 7.89 385% ,0.0001
Lymphocyte CD4 .500 cells/ml for 180 days
Yes vs. no 8 (4.3) 82 (26.1) 4.16 1.95 8.88 316% ,0.0001
Latest Lymphocyte CD4 count .100 cells/ml
Yes vs. no 47 (10.9) 47 (64.4) 5.44 3.39 8.74 444% ,0.0001
Diagnosis of AIDS (ever during follow-up)
No vs. yes 33 (10.5) 64 (33.2) 1.69 1.03 2.79 69% 0.039
Selection of factors was based on Akaike Information Criterion (AIC) and statistical significance.
doi:10.1371/journal.pone.0022215.t003
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Brumme et al. [23], who observed improved survival in the
median .5 year period after starting the antiretroviral therapy in
the univariate analysis adjusted for baseline age, lymphocyte CD4
count, viral load and AIDS defining conditions.
In our study the number of AIDS-free individuals with the
CCR5 D32 variant was significantly higher at the time of HIV
diagnosis, however for the entire follow-up period the number of
AIDS cases was not notably different between the groups with and
without this allele. This could be related to the fact that the cohort
used for this analysis consisted of a large number of late diagnosed
individuals, in 372 (73.4%) cases infection was diagnosed in either
the symptomatic stage or with baseline CD4 count,350 cells/ml,
which is characteristic for HIV infections diagnosed in Poland
Figure 6. Kaplan-Meyer plots presenting the CCR5 D32/wt genotype based survival prior to cART introduction (a) and on
antiretroviral therapy (b).
doi:10.1371/journal.pone.0022215.g006
Figure 5. Hazard ratio changes during observation period. For calculation multivariate Cox regression adjusted for the six selected factors
was used. Upper and lower confidence intervals are indicated as the external limits in the plot. For the values of borderline significance (p=0.1–0.50)
the field is marked in green while values of statistical significance (P,0.05) are marked in blue. a-CCR5 genotype, b- gender, c-antiretroviral treatment
history, d- CD4 count .500 cells/ml maintained for at least half a year, e-the most recent CD4 count of 100 cells/ml, f- AIDS diagnosis.
doi:10.1371/journal.pone.0022215.g005
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to the time-dependency of the beneficial effect, as reported before
[25,26]. Similarly, the slightly higher prevalence of the D32 allele
among antiretroviral naive patients is probably related to a higher
number of patients asymptomatic at baseline who would not
require cART. Other differences of borderline statistical signifi-
cance for the CCR5 D32 allele frequency include a lower frequency
among women, confirming the finding by Philpott et al., of a more
extensive protective effect of the CCR5 D32/wt heterozygous
genotype in women [27] while a lower prevalence of the
heterozygotes among heterosexually infected patients might be
related to the fact that high CCR5 levels are required for these
primarily macrophage-tropic sexual infections [28,29].
In the univariate analysis of all the factors significantly
modifying all-cause mortality the strongest protective effect was
observed for cART as well as CD4 metrics, namely nadir, zenith
lymphocyte CD4, time with CD4 count above 500 cells/ml and
AIDS-free observation. Effects of these parameters were exten-
sively studied before and remain well documented [30–33]. These
influences might be additionally modified by the D32 allele, found
also to be a statistically significant protective influence on
mortality, as it has been reported that in individuals bearing this
variant time of progression to AIDS after initiation of cART as
well as time from AIDS diagnosis to death is increased [25,11]. In
our study the D32 allele was associated with decreased mortality
risk observed for as long as 15 years of follow-up. This association
remained significant after adjustment for other factors strongly
influencing mortality: gender, nadir and zenith CD4 count, time
with CD4 .500 cells/ml, most recent CD4 levels and AIDS
diagnosis.
It must be noted, that the CCR5 D32/wt genotype was
associated with better survival in untreated individuals only,
which is probably associated to the slower development of the
symptomatic disease as suggested by Brumme et al., [34] while
among cART treated individuals the correlation with better
survival was insignificant, however this analysis was performed on
smaller number of patients (55 with the CCR5 D32/wt genotype
with 23 on cART for 5 years and 6 for more than 10 years). No
significant effect of the D32 allele, survival and AIDS free survival
was also found by Laurichesse et al. [8]. Moreover, Brumme et al.,
did not find the association between the CCR5 D32/wt genotype
and time to virological failure in the study of 436 individuals
observed for the median follow-up of 22 months [22]. Similarly,
Bratt et al, in the study of 147 patients, which included similar
(37%) percentage of AIDS diagnosed patients as our analysis,
observed little influence of the CCR5 D32/wt genotype on virologic
treatment efficacy [35]. Lack of beneficial effect of the D32 allele
among antiretroviral treated patients observed in our study might
be associated not only to the size of the group, but also differences
in the time from the infection to treatment initiation, which is
related to late diagnosis of HIV and high prevalence of AIDS at
the time of diagnosis. However, it must be noted that the D32
allele has been associated with the decrease in the likelihood of
viral suppression failures, defined as HIV-RNA $200 copies/ml
at 16–28 weeks of therapy, accelerated viral suppression to ,200
HIV-RNA copies/ml, as well as significantly better virologic
response to antiretrovirals both at 6 and 12 months following
treatment initiation [8,11,36]. Moreover, a higher rate of the
sustained virologic suppression during the observation period of up
to 5 years of antiretroviral treatment in the CCR5 D32/wt
heterozygous patients was noted [9].
In adjusted multivariate analyses both AIDS diagnosis and
antiretroviral treatment remained significant predictors of mortal-
ity. Moreover, it was confirmed that of all the CD4 metrics
studied, the latest CD4 count is the strongest predictor of
mortality, as has been suggested before [37]. When the time-
dependency for the six factors included into the multivariate model
was studied, a continuous significant positive effect, regardless the
period of observation both for this variable and history of cART,
was observed. This confirms the value of these parameters and
emphasizes the need for early introduction of the antiretroviral
treatment. Stable CD4 count of .500 cells/ml for at least 180 days
became a significant parameter after 30 months of observation,
which is probably related to the time dependent immune recovery.
Interestingly, the continuous protective effect of the CCR5 D32/wt
genotype was observed over 36 months of follow-up with stable
HR of 2.5–2.6 noted up to 96 months, the end of observation
period. This suggests that in the cART era the protective effect of
this variant on survival is not lost over time as was observed for the
D32 allele and AIDS diagnosis. Hazard ratio effect plots for gender
and diagnosis of AIDS proved time-dependent, with female
gender associated with significant protection up to 108 month of
observation while for AIDS two periods associated with favorable
prognosis in AIDS free patients were noted, namely from months
36 to 54 and 108 to 180 months. The reason for this time
dependent relationship remains to be elucidated.
Studies analyzing the impact of the CCR5 D32 deletion on long
term survival among HIV (+) patients in the cART era remain
sparse, especially with implementation of Cox regression models
adjusted for clinical variables significantly contributing to the
mortality risk.
A potential limitation of the study was use of interval censoring
for six cases when the exact date was unknown, with the death
date fixed as the median date between the last observation time
and information that the patients actually died. Another limitation
is related to the lack of possibility to observe the patients from the
time of seroconversion, however in the setting of the late testing
and referral of majority of cases with symptomatic immunodefi-
ciency such a study was not feasible. Another limitation is related
to the lack of information on adherence, therefore the results could
not be controlled for this factor.
Host genetics strongly interacts with HIV leading to the
modification of the course of infection. Our finding of the
beneficial effect of the CCR5 D32 on long term survival in
conjunction with well established factors influencing mortality
provides an insight into the interplay between genetic and virus/
host-related factors. Such an effect is of the greatest importance in
the late-tested populations, such as the one in Poland, allowing for
the longer period of delay from infection to disease detection and
treatment initiation, whereas it is of the lesser importance in the
cART treated individuals. Testing for the CCR5 D32 mutation in
clinical practice might be useful for elucidation of the reason for
delayed progression of HIV infection, however it should probably
not influence decision on antiretroviral treatment initiation or
modification.
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